To compare the incidence of diabetic ketoacidosis (DKA) among patients with type 2 diabetes mellitus (T2DM) who were new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) versus other classes of antihyperglycemic agents (AHAs).
defined narrowly to exclude possible misclassified patients, an increased risk of DKA with SGLT2i was observed compared with sulfonylureas. KEYWORDS diabetic ketoacidosis, SGLT2 inhibitor, type 2 diabetes 1 | INTRODUCTION Diabetic ketoacidosis (DKA) is a serious acute metabolic complication of diabetes, characterized by hyperglycemia, ketosis, and metabolic acidosis. 1 The underlying pathophysiology of DKA is an absolute or relative insulin deficiency, increased insulin counter-regulatory hormones, and peripheral insulin resistance. 1 DKA is often precipitated by stressful conditions such as trauma, surgery, or infection and is more common in patients with type 1 diabetes mellitus (T1DM) than in patients with type 2 diabetes mellitus (T2DM). 2, 3 The incidence of DKA among patients with T1DM ranged from 8 to 56 per 1000 patient-years in larger studies in the United States, Canada, Europe, and Israel. 4 In comparison, a much lower DKA incidence of <2 per 1000 patient-years was reported in cohort studies of adults with T2DM in clinical practice. [5] [6] [7] Sodium glucose co-transporter 2 (SGLT2) inhibitors are oral antihyperglycemic agents (AHAs) that lower blood glucose by increasing urinary glucose excretion. 8 Currently, four SGLT2 inhibitors are approved in the United States and Europe for the treatment of T2DM: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. [9] [10] [11] [12] [13] [14] [15] [16] In 2015, the US Food and Drug Administration (FDA) issued a Drug Safety Communication about the risk of ketoacidosis with SGLT2 inhibitors based on postmarketing adverse event reporting, and a warning was subsequently added to the label of all SGLT2 inhibitors. 17 In 2016, on the recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC), the European Medicines Agency (EMA) listed DKA as a rare adverse reaction in the product information of SGLT2 inhibitors and implemented risk management measures to minimize this risk. 18 Of note, patients taking SGLT2 inhibitors may present with atypical DKA (no marked hyperglycemia) because of SGLT2 inhibitors' glycosuria effect, which can delay diagnosis and treatment. 18 Most clinical development programs of SGLT2 inhibitors, including canagliflozin, dapagliflozin, empagliflozin, as well as meta-analyses of randomized controlled trials, have reported a low frequency of DKA events in patients with T2DM, with a numerically higher rate for SGLT2 inhibitors as a class or individual agent relative to placebo and active controls. [19] [20] [21] [22] [23] [24] [25] [26] Real-world studies of DKA among new users of SGLT2 inhibitors are limited, particularly in patients with T2DM. An increased risk of DKA with SGLT2 inhibitor treatment was observed in some, but not all, studies. 6, 7, 27, 28 Limitations of prior studies include small sample size and number of events, specific patient population, and select treatment comparators.
The current study sought to estimate the incidence rate and further evaluate the comparative risk of DKA among patients with T2DM in routine clinical practice who were new users of SGLT2 inhibitors versus new users of other classes of AHAs using data from four large US claims databases.
| METHODS

| Study design
This was a retrospective, observational, comparative cohort study. The study protocol has been reviewed and approved by the EMA PRAC as a postauthorization safety study (PASS) and is available at https:// github.com/OHDSI/StudyProtocols/tree/master/Sglt2iDka/ documents. 
| Data source
| New-user cohort categorization
| Outcomes
The primary outcome of this study was the first DKA event that occurred after the index date of an AHA therapy, identified from a diagnosis code recorded in inpatient or emergency room claims. To be considered an incident event, DKA occurring after exposure to a new AHA had to occur ≥30 days after any pre-index DKA event. Fatal DKA was defined as death at discharge from the hospitalized DKA event, whereas this information could not be assessed in the Optum database. As laboratory tests were not systematically collected in the databases used for this study, DKA cases could not be validated using lab tests or categorized as typical or atypical DKA.
| Statistical analyses
Analyses were performed in SQL and R. 30 
| Descriptive analyses
The unadjusted incidence rates of DKA were expressed as number of incident events per 1000 patient-years and were also stratified by subgroups of age, sex, history of DKA, and history of insulin use. Index) as candidate predictors. 31 The model used a cyclic coordinate descending method with least absolute shrinkage and selection operator (LASSO), and the regularization hyperparameter was selected by optimizing the likelihood in a 10-fold cross validation. 32, 33 Conventional greedy algorithms with nearest neighbor that minimize the absolute difference between the PS were used for matching. 34 The maximum matching caliper was 20% of the SD of the logit of the PS. 35 Evaluations of the history of DKA and prior AHA therapies considered all available claims records prior to the exposure index date. Conditional Cox proportional hazards models were used to estimate the hazard ratio (HR) of DKA in the SGLT2 inhibitor cohort versus the comparator cohort, with each PS-matched set treated as a separate stratum in the model. For each comparison, the P value was calibrated against an empirical null distribution estimated using 43 negative control outcomes to address potential systematic bias (Supplemental Table 1 ). 36 HRs were estimated in each database separately. When the I 2 was <40%, a pooled HR across the four databases was generated using a random effects approach, 37 in which the standard errors of the database-specific estimates were adjusted to incorporate variation of effects across databases, the across-database variance was estimated by comparing the result of each database with the result of an inverse-variance fixed-effects meta-analysis.
| Comparative analyses
| Sensitivity analyses
First, a modified DKA definition was used where cases were identified by inpatient claims only. Second, change of AHA treatment was considered for cohort follow-up, in which censoring was applied to the time-at-risk at the initiation of non-index AHAs as well as at the discontinuation of the index AHA (defined as refill gap of ≥90 days from the day the index AHA supply from the previous prescription was expected to run out).
| RESULTS
All results have been made publicly available through an interactive web-based application at http://data.ohdsi.org/Sglt2iDka/. This section summarizes the key findings across these results.
| Study population
Of the four claims databases, CCAE provided the largest sample size for all AHA new-user cohorts, and MDCD provided the smallest sample size for most cohorts (Supplemental Table 2 (Table 1 and Supplemental Table 3 ). The corresponding incidence rates using the narrow definition of T2DM ranged from 1.15 to 3.91 per 1000 patient-years in the all SGLT2 inhibitor cohorts and from 0.75 to 7.94 per 1000 patient-years in the comparator cohorts. In general, the incidence rates were highest in MDCD, followed by Optum, and lowest in CCAE and MDCR.
Overall, the proportion of fatal DKA events was low, although it varied across databases and AHA cohorts (Supplemental Table 4 ). In general, the case fatality is higher in MDCR and MDCD than in CCAE.
Among new users of SGLT2 inhibitors, the highest fatality was observed in MDCD (1.9% and 3.1% using the broad and narrow definitions of T2DM, respectively). Among new users of comparator AHAs, the highest fatality was observed in MDCR (6.3% and 8.9%
using the broad and narrow definitions of T2DM, respectively).
| Risk factors and preceding events
The unadjusted incidence rates of DKA were higher in patients with prior use of insulin and history of DKA (data not shown). A higher proportion of new users of SGLT2 inhibitors who had incident DKA events received a prescription for insulin prior to the index date compared with new users of comparator AHAs who had incident DKA events, except for GLP-1 receptor agonists (Supplemental Table 5 ).
Other risk factors for DKA and events that occurred prior to DKA (eg, hospitalization, surgery, and infections) were similarly distributed across the AHA new-user cohorts.
| Risk of DKA in the PS-matched cohorts
Baseline characteristics prior to the AHA exposure index date, including demographics, comorbidities, and medications, were well balanced after PS matching for all matched cohorts (data not shown).
Using the broad definition of T2DM, a significantly increased risk of DKA was observed in new users of SGLT2 inhibitors compared with SU, DPP-4 inhibitors, GLP-1 receptor agonists, metformin, and insulinotropic AHAs in select individual databases and the meta-analysis (Figure 1 and Supplemental Figure 1A) . Meta Figures 2-4 ).
| Sensitivity analyses
In sensitivity analyses identifying DKA events from inpatient diagnoses only (Supplemental Table 6 ) and censoring time-at-risk at the regimen change (Figure 2 and Supplemental Figure 1B) , the HRs of DKA for new users of SGLT2 inhibitors versus comparator AHAs were generally consistent with the main analyses, although with fewer cases and less precision. The current study strengthens the real-world evidence by its use of four large claims databases, which are likely representative of routine clinical practice for US patients with insurance coverage, and comprehensive analyses comparing SGLT2 inhibitors as a class, as well as by individual agent, with multiple comparators. Nevertheless, this 
